Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Lifted by Garden State Investment Advisory Services LLC

Garden State Investment Advisory Services LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 956 shares of the medical equipment provider’s stock after acquiring an additional 70 shares during the quarter. Garden State Investment Advisory Services LLC’s holdings in Intuitive Surgical were worth $425,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. One Wealth Management Investment & Advisory Services LLC grew its holdings in shares of Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after buying an additional 23 shares in the last quarter. Indiana Trust & Investment Management CO increased its holdings in shares of Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares during the period. Hoxton Planning & Management LLC lifted its position in shares of Intuitive Surgical by 4.9% in the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 25 shares in the last quarter. First Affirmative Financial Network boosted its holdings in shares of Intuitive Surgical by 2.7% during the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 26 shares during the period. Finally, Moors & Cabot Inc. grew its position in Intuitive Surgical by 2.3% during the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after purchasing an additional 26 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $486.20 on Friday. The stock’s 50-day moving average is $468.01 and its 200-day moving average is $424.86. The company has a market cap of $172.46 billion, a P/E ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the business posted $1.18 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now directly owns 295 shares in the company, valued at approximately $145,113.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at approximately $145,113.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert Desantis sold 1,413 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,414,931.60. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock worth $25,528,753 in the last ninety days. 0.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on ISRG. BTIG Research lifted their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Morgan Stanley upped their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Barclays lifted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Finally, Evercore ISI dropped their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.